{"protocolSection":{"identificationModule":{"nctId":"NCT00609518","orgStudyIdInfo":{"id":"11652"},"secondaryIdInfos":[{"id":"H3E-CR-S111","type":"OTHER","domain":"Eli Lilly and Company"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"A Study for Patients With Non-Squamous Non-Small Cell Lung Cancer","officialTitle":"Pemetrexed With Simplified Folate and Dexamethasone Supplementation Versus Pemetrexed With Standard Supplementation as Second-line Chemotherapy for Patients With Non-squamous Non-small Cell Lung Cancer"},"statusModule":{"statusVerifiedDate":"2010-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2008-02"},"primaryCompletionDateStruct":{"date":"2009-10","type":"ACTUAL"},"completionDateStruct":{"date":"2010-06","type":"ACTUAL"},"studyFirstSubmitDate":"2008-01-23","studyFirstSubmitQcDate":"2008-01-23","studyFirstPostDateStruct":{"date":"2008-02-07","type":"ESTIMATED"},"resultsFirstSubmitDate":"2010-10-15","resultsFirstSubmitQcDate":"2010-10-15","resultsFirstPostDateStruct":{"date":"2010-11-15","type":"ESTIMATED"},"lastUpdateSubmitDate":"2010-12-10","lastUpdatePostDateStruct":{"date":"2010-12-28","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"oldNameTitle":"Chief Medical Officer","oldOrganization":"Eli Lilly"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"Chemotherapy for patients with non-squamous non-small cell lung cancer. Patients are given folic acid, vitamin B12 and steroids, both before and during treatment, to reduce the side effects associated with pemetrexed. The aim is whether it is possible to simplify the folic acid and steroid schedule without increasing toxicity."},"conditionsModule":{"conditions":["Non Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":111,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Standard Vitamin and Steroid Schedule + Pemetrexed","type":"ACTIVE_COMPARATOR","description":"Standard vitamin and steroid schedule that is used with pemetrexed consisting of a minimum of 5 daily doses of folic acid before first pemetrexed dose and dexamethasone on day before, day of, and day after treatment.","interventionNames":["Drug: pemetrexed","Dietary Supplement: Folic acid","Dietary Supplement: Vitamin B12","Drug: dexamethasone"]},{"label":"Simplified Vitamin and Steroid Schedule + Pemetrexed","type":"EXPERIMENTAL","description":"Simplified vitamin and steroid schedule to be used with pemetrexed consisting of 2 daily doses of folic acid before first pemetrexed dose and dexamethasone on day of treatment only.","interventionNames":["Drug: pemetrexed","Dietary Supplement: Folic Acid","Dietary Supplement: Vitamin B12","Drug: dexamethasone"]}],"interventions":[{"type":"DRUG","name":"pemetrexed","description":"500 mg/m\\^2 intravenous infusion on day 1 of each 21-day cycle. Number of Cycles: Until progression or to a maximum of 6 cycles.","armGroupLabels":["Simplified Vitamin and Steroid Schedule + Pemetrexed","Standard Vitamin and Steroid Schedule + Pemetrexed"],"otherNames":["Alimta","LY231514"]},{"type":"DIETARY_SUPPLEMENT","name":"Folic acid","description":"350-1000 micrograms taken orally for at least 5 daily doses during the 7-day period prior to the first dose of pemetrexed then continues daily throughout treatment until 3 weeks after the last dose of pemetrexed.","armGroupLabels":["Standard Vitamin and Steroid Schedule + Pemetrexed"],"otherNames":["Folate"]},{"type":"DIETARY_SUPPLEMENT","name":"Folic Acid","description":"350-1000 micrograms taken orally for two consecutive daily doses of folic acid the day before and the day of the first dose of pemetrexed the continues throughout treatment and for 3 weeks after the last dose of pemetrexed.","armGroupLabels":["Simplified Vitamin and Steroid Schedule + Pemetrexed"],"otherNames":["Folate"]},{"type":"DIETARY_SUPPLEMENT","name":"Vitamin B12","description":"1000 micrograms intramuscular injection of vitamin B12 during the week prior to the first dose of pemetrexed then further injections given approximately every 9 weeks until 3 weeks after the last dose of pemetrexed.","armGroupLabels":["Simplified Vitamin and Steroid Schedule + Pemetrexed","Standard Vitamin and Steroid Schedule + Pemetrexed"]},{"type":"DRUG","name":"dexamethasone","description":"4 mg taken orally \\[or equivalent\\] twice per day the day before, the day of, and the day after the first day of pemetrexed. Continue to give dexamethasone twice per day the day before, the day of, and the day after each dose of pemetrexed.","armGroupLabels":["Standard Vitamin and Steroid Schedule + Pemetrexed"]},{"type":"DRUG","name":"dexamethasone","description":"4 mg taken orally \\[or equivalent\\] twice per day on the day of the first dose of pemetrexed. Continue to give dexamethasone twice per day on the day of each dose of pemetrexed.","armGroupLabels":["Simplified Vitamin and Steroid Schedule + Pemetrexed"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Safety: Number of Participants With Drug-Related Grade 3 or 4 Toxicity","description":"Results are presented for the number of participants with drug-related Grade 3 or 4 toxicity/adverse event (AE). Grades range from 0 (none) to 5 (death), with Grade 3 and 4 being defined as follows:\n\nGrade 0 = No AE; Grade 1 = Mild AE; Grade 2 = Moderate AE; Grade 3 = Severe AE; Grade 4 = Life-threatening or disabling AE; Grade 5 = Death related to AE. A detailed list of Serious and non-serious adverse events is provided in the Reported Adverse Event section.","timeFrame":"From first dose of treatment to last dose of treatment plus 30 days"}],"secondaryOutcomes":[{"measure":"Proportion of Participants With Best Overall Tumor Response (Response Rate)","description":"Response defined per Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR)=disappearance of all target lesions; Partial Response (PR)=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria. Best Overall Tumor Response is complete response plus partial response.","timeFrame":"Baseline until disease progression, new therapy initiated, or death from any cause, up to 12 months after enrollment."},{"measure":"Overall Survival","description":"Overall survival is the duration from randomization to death. For patients who are alive, overall survival is censored at the date of last contact.","timeFrame":"Randomization (≤4 weeks from baseline visit) to 12 months after randomization"},{"measure":"Progression-free Survival (PFS)","description":"Defined as the time from date of first dose to the first observation of disease progression, or death due to any cause. For patients who are alive and have not progressed, PFS is censored at the date of last radiological assessment.","timeFrame":"Randomization (≤4 weeks from baseline visit) to 12 months after randomization"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologic or cytologic diagnosis of non-small cell lung cancer (NSCLC) with locally advanced or metastatic disease (Stage IIIA, IIIB or IV)that is of non-squamous histology\n* Patients must have failed only one prior chemotherapy regime and must be considered eligible for further chemotherapy following progression of their disease.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2\n* Adequate organ function\n\nExclusion Criteria:\n\n* Concurrent administration of any other anti-tumor therapy\n* Other co-existing malignancies\n* Pregnancy or breast feeding\n* Serious concomitant disorders\n* Inability or unwillingness to take folic acid or vitamin B12 supplementation","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Bankstown","state":"New South Wales","zip":"2200","country":"Australia","geoPoint":{"lat":-33.91667,"lon":151.03333}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Concord","state":"New South Wales","zip":"2139","country":"Australia","geoPoint":{"lat":-33.84722,"lon":151.10381}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Kingswood Penrith","state":"New South Wales","zip":"2747","country":"Australia"},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Liverpool","state":"New South Wales","zip":"2170","country":"Australia","geoPoint":{"lat":-33.91938,"lon":150.92588}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Redcliffe","state":"Queensland","zip":"4020","country":"Australia","geoPoint":{"lat":-27.22649,"lon":153.10648}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Bologna","zip":"40100","country":"Italy","geoPoint":{"lat":44.49381,"lon":11.33875}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Milan","zip":"20132","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Napoli","zip":"80100","country":"Italy","geoPoint":{"lat":40.87618,"lon":14.5195}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Pisa","zip":"56100","country":"Italy","geoPoint":{"lat":43.70853,"lon":10.4036}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Rome","zip":"00149","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Mexico City","zip":"14000","country":"Mexico","geoPoint":{"lat":19.42847,"lon":-99.12766}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Toluca","zip":"CP50180","country":"Mexico","geoPoint":{"lat":19.28786,"lon":-99.65324}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Pozuelo de Alarcón","zip":"28223","country":"Spain","geoPoint":{"lat":40.43293,"lon":-3.81338}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Seville","zip":"41014","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Lilly Clinical Trial Registry","url":"http://www.lillytrials.com"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Completed is defined as:The patient has completed follow-up visits until 12 months after the randomization date.\n\nQualified Intent-to-Treat (Q-ITT) is defined as: Include all randomized patients, with nonsquamous histology, who comply with their pretreatment folic acid and steroid supplementation schedule and take at least one dose of pemetrexed.","groups":[{"id":"FG000","title":"Standard Vitamin and Steroid Schedule + Pemetrexed","description":"Standard vitamin and steroid schedule that is used with pemetrexed consisting of a minimum of 5 daily doses of folic acid before first pemetrexed dose and dexamethasone on day before, day of, and day after treatment."},{"id":"FG001","title":"Simplified Vitamin and Steroid Schedule + Pemetrexed","description":"Simplified vitamin and steroid schedule to be used with pemetrexed consisting of 2 daily doses of folic acid before first pemetrexed dose and dexamethasone on day of treatment only."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"54"},{"groupId":"FG001","numSubjects":"57"}]},{"type":"Completed 6 Treatment Cycles","achievements":[{"groupId":"FG000","numSubjects":"19"},{"groupId":"FG001","numSubjects":"22"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"17"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"43"},{"groupId":"FG001","numSubjects":"40"}]}],"dropWithdraws":[{"type":"Death from Study Disease","reasons":[{"groupId":"FG000","numSubjects":"32"},{"groupId":"FG001","numSubjects":"32"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Death from Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Standard Vitamin and Steroid Schedule + Pemetrexed","description":"Standard vitamin and steroid schedule that is used with pemetrexed consisting of a minimum of 5 daily doses of folic acid before first pemetrexed dose and dexamethasone on day before, day of, and day after treatment."},{"id":"BG001","title":"Simplified Vitamin and Steroid Schedule + Pemetrexed","description":"Simplified vitamin and steroid schedule to be used with pemetrexed consisting of 2 daily doses of folic acid before first pemetrexed dose and dexamethasone on day of treatment only."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"54"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"111"}]}],"measures":[{"title":"Age Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"62.1","spread":"11.08"},{"groupId":"BG001","value":"60.9","spread":"12.13"},{"groupId":"BG002","value":"61.4","spread":"11.60"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"40"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"32"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"71"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Spain","categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"17"}]}]},{"title":"Mexico","categories":[{"measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"54"}]}]},{"title":"Italy","categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"33"}]}]},{"title":"Australia","categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"7"}]}]}]},{"title":"Eastern Cooperative Oncology Group (ECOG) Performance Status","description":"Classifies patients according to their functional impairment. Scores range from 0 (Fully Active) to 5 (Death).","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"0- Fully Active","categories":[{"measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"52"}]}]},{"title":"1- Ambulatory, Restricted Strenuous Activity","categories":[{"measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"56"}]}]},{"title":"2- Ambulatory, No Work Activities","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}]}]},{"title":"Not Assessed","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}]}]},{"title":"Smoking Status","paramType":"NUMBER","unitOfMeasure":"Participants","classes":[{"title":"Past Smoker","categories":[{"measurements":[{"groupId":"BG000","value":"32"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"65"}]}]},{"title":"Never Smoked","categories":[{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"29"}]}]},{"title":"Current Smoker","categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"17"}]}]}]},{"title":"Pathological Diagnosis","paramType":"NUMBER","unitOfMeasure":"Participants","classes":[{"title":"Cytological","categories":[{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"38"}]}]},{"title":"Histopathological","categories":[{"measurements":[{"groupId":"BG000","value":"37"},{"groupId":"BG001","value":"36"},{"groupId":"BG002","value":"73"}]}]}]},{"title":"Disease Stage","description":"Stage means how big the tumor is and how far it has spread. Stages range from 0 (not spread) to IV (spread throughout the body). Differentiation between stage IIIA and IIIB is in accordance with the American Joint Committee on Cancer Staging Criteria for Lung Cancer.","paramType":"NUMBER","unitOfMeasure":"Participants","classes":[{"title":"IIIA","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"}]}]},{"title":"IIIB","categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"22"}]}]},{"title":"IV","categories":[{"measurements":[{"groupId":"BG000","value":"42"},{"groupId":"BG001","value":"43"},{"groupId":"BG002","value":"85"}]}]}]},{"title":"Body Mass Index (BMI)","description":"Body mass index is an estimate of body fat based on body weight divided by height squared (kilograms/square meters \\[kg/m\\^2\\]).","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kg/m^2","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"25.3","spread":"3.98"},{"groupId":"BG001","value":"26.0","spread":"5.20"},{"groupId":"BG002","value":"25.7","spread":"4.64"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Safety: Number of Participants With Drug-Related Grade 3 or 4 Toxicity","description":"Results are presented for the number of participants with drug-related Grade 3 or 4 toxicity/adverse event (AE). Grades range from 0 (none) to 5 (death), with Grade 3 and 4 being defined as follows:\n\nGrade 0 = No AE; Grade 1 = Mild AE; Grade 2 = Moderate AE; Grade 3 = Severe AE; Grade 4 = Life-threatening or disabling AE; Grade 5 = Death related to AE. A detailed list of Serious and non-serious adverse events is provided in the Reported Adverse Event section.","populationDescription":"Qualified Intention to Treat (Q-ITT)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"From first dose of treatment to last dose of treatment plus 30 days","groups":[{"id":"OG000","title":"Standard Vitamin and Steroid Schedule + Pemetrexed","description":"Standard vitamin and steroid schedule that is used with pemetrexed consisting of a minimum of 5 daily doses of folic acid before first pemetrexed dose and dexamethasone on day before, day of, and day after treatment."},{"id":"OG001","title":"Simplified Vitamin and Steroid Schedule + Pemetrexed","description":"Simplified vitamin and steroid schedule to be used with pemetrexed consisting of 2 daily doses of folic acid before first pemetrexed dose and dexamethasone on day of treatment only."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"47"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"18"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","statisticalMethod":"Linear probability model","paramType":"Risk Difference (RD)","paramValue":"0.09","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.10","ciUpperLimit":"0.28"}]},{"type":"SECONDARY","title":"Proportion of Participants With Best Overall Tumor Response (Response Rate)","description":"Response defined per Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR)=disappearance of all target lesions; Partial Response (PR)=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria. Best Overall Tumor Response is complete response plus partial response.","populationDescription":"Qualified Intent to Treat (Q-ITT)","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"proportion of patients","timeFrame":"Baseline until disease progression, new therapy initiated, or death from any cause, up to 12 months after enrollment.","groups":[{"id":"OG000","title":"Standard Vitamin and Steroid Schedule + Pemetrexed","description":"Standard vitamin and steroid schedule that is used with pemetrexed consisting of a minimum of 5 daily doses of folic acid before first pemetrexed dose and dexamethasone on day before, day of, and day after treatment."},{"id":"OG001","title":"Simplified Vitamin and Steroid Schedule + Pemetrexed","description":"Simplified vitamin and steroid schedule to be used with pemetrexed consisting of 2 daily doses of folic acid before first pemetrexed dose and dexamethasone on day of treatment only."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"47"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.118","lowerLimit":"0.044","upperLimit":"0.239"},{"groupId":"OG001","value":"0.064","lowerLimit":"0.013","upperLimit":"0.175"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.4902","statisticalMethod":"Fisher Exact","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Overall Survival","description":"Overall survival is the duration from randomization to death. For patients who are alive, overall survival is censored at the date of last contact.","populationDescription":"Qualified Intent to Treat (Q-ITT)","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Randomization (≤4 weeks from baseline visit) to 12 months after randomization","groups":[{"id":"OG000","title":"Standard Vitamin and Steroid Schedule + Pemetrexed","description":"Standard vitamin and steroid schedule that is used with pemetrexed consisting of a minimum of 5 daily doses of folic acid before first pemetrexed dose and dexamethasone on day before, day of, and day after treatment."},{"id":"OG001","title":"Simplified Vitamin and Steroid Schedule + Pemetrexed","description":"Simplified vitamin and steroid schedule to be used with pemetrexed consisting of 2 daily doses of folic acid before first pemetrexed dose and dexamethasone on day of treatment only."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"47"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","lowerLimit":"5.4","upperLimit":"11.7"},{"groupId":"OG001","value":"9.2","lowerLimit":"7.6","upperLimit":"11.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.6791","statisticalMethod":"Log Rank","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","statisticalMethod":"Regression, Cox","statisticalComment":"Treatment was the covariate included in this model.","paramType":"Hazard Ratio (HR)","paramValue":"0.90","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.54","ciUpperLimit":"1.49"}]},{"type":"SECONDARY","title":"Progression-free Survival (PFS)","description":"Defined as the time from date of first dose to the first observation of disease progression, or death due to any cause. For patients who are alive and have not progressed, PFS is censored at the date of last radiological assessment.","populationDescription":"Qualified Intent to Treat (Q-ITT)","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Randomization (≤4 weeks from baseline visit) to 12 months after randomization","groups":[{"id":"OG000","title":"Standard Vitamin and Steroid Schedule + Pemetrexed","description":"Standard vitamin and steroid schedule that is used with pemetrexed consisting of a minimum of 5 daily doses of folic acid before first pemetrexed dose and dexamethasone on day before, day of, and day after treatment."},{"id":"OG001","title":"Simplified Vitamin and Steroid Schedule + Pemetrexed","description":"Simplified vitamin and steroid schedule to be used with pemetrexed consisting of 2 daily doses of folic acid before first pemetrexed dose and dexamethasone on day of treatment only."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"47"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","lowerLimit":"2.9","upperLimit":"4.9"},{"groupId":"OG001","value":"3.8","lowerLimit":"1.8","upperLimit":"5.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.5870","statisticalMethod":"Log Rank","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","statisticalMethod":"Regression, Cox","statisticalComment":"Treatment was the covariate included in this model.","paramType":"Hazard Ratio (HR)","paramValue":"0.89","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.57","ciUpperLimit":"1.38"}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"Standard Vitamin and Steroid Schedule + Pemetrexed","description":"Standard vitamin and steroid schedule that is used with pemetrexed consisting of a minimum of 5 daily doses of folic acid before first pemetrexed dose and dexamethasone on day before, day of, and day after treatment.","seriousNumAffected":18,"seriousNumAtRisk":54,"otherNumAffected":47,"otherNumAtRisk":54},{"id":"EG001","title":"Simplified Vitamin and Steroid Schedule + Pemetrexed","description":"Simplified vitamin and steroid schedule to be used with pemetrexed consisting of 2 daily doses of folic acid before first pemetrexed dose and dexamethasone on day of treatment only.","seriousNumAffected":18,"seriousNumAtRisk":57,"otherNumAffected":54,"otherNumAtRisk":57}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":57}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":57}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":57}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":57}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":57}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Sinus tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":57}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Gastrointestinal inflammation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":57}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":57}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":57}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":57}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":57}]},{"term":"Bronchiectasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":57}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":57}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Lobar pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":57}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":57}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":57}]},{"term":"Humerus fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":57}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":57}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":57}]},{"term":"Malignant pleural effusion","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":57}]},{"term":"Tumour pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Ataxia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":57}]},{"term":"Complex regional pain syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":57}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":57}]},{"term":"Acute pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":57}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":57}]},{"term":"Hydropneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Laryngeal oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Oesophagobronchial fistula","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":57}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":54},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":57}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":57}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":57}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":57}]},{"term":"Erythema multiforme","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":57}]},{"term":"Swelling face","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":57}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":13,"numAtRisk":54},{"groupId":"EG001","numEvents":24,"numAffected":18,"numAtRisk":57}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":8,"numAtRisk":54},{"groupId":"EG001","numEvents":36,"numAffected":18,"numAtRisk":57}]},{"term":"Lymphopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":54},{"groupId":"EG001","numEvents":20,"numAffected":15,"numAtRisk":57}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":13,"numAtRisk":54},{"groupId":"EG001","numEvents":31,"numAffected":17,"numAtRisk":57}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":54},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":57}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":54},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":57}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":54},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":57}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":54},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":57}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":11,"numAtRisk":54},{"groupId":"EG001","numEvents":21,"numAffected":19,"numAtRisk":57}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":6,"numAtRisk":54},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":57}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":14,"numAtRisk":54},{"groupId":"EG001","numEvents":14,"numAffected":14,"numAtRisk":57}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":54},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":57}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":54},{"groupId":"EG001","numEvents":9,"numAffected":7,"numAtRisk":57}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":9,"numAffected":6,"numAtRisk":57}]},{"term":"Hyperbilirubinaemia","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":57}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":6,"numAtRisk":54},{"groupId":"EG001","numEvents":15,"numAffected":9,"numAtRisk":57}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":2,"numAtRisk":54},{"groupId":"EG001","numEvents":11,"numAffected":6,"numAtRisk":57}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":54},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":57}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":57}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":57}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":54},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":57}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":54},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":57}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":57}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":57}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":57}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":54},{"groupId":"EG001","numEvents":13,"numAffected":11,"numAtRisk":57}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":54},{"groupId":"EG001","numEvents":13,"numAffected":11,"numAtRisk":57}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":54},{"groupId":"EG001","numEvents":9,"numAffected":7,"numAtRisk":57}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","phone":"800-545-5979"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068437","term":"Pemetrexed"},{"id":"D005492","term":"Folic Acid"},{"id":"D014805","term":"Vitamin B 12"},{"id":"D003907","term":"Dexamethasone"}],"ancestors":[{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"},{"id":"D011622","term":"Pterins"},{"id":"D011621","term":"Pteridines"},{"id":"D045728","term":"Corrinoids"},{"id":"D045725","term":"Tetrapyrroles"},{"id":"D011758","term":"Pyrroles"},{"id":"D001393","term":"Azoles"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D006576","term":"Heterocyclic Compounds, 4 or More Rings"},{"id":"D047028","term":"Macrocyclic Compounds"},{"id":"D011083","term":"Polycyclic Compounds"},{"id":"D011246","term":"Pregnadienetriols"},{"id":"D011245","term":"Pregnadienes"},{"id":"D011278","term":"Pregnanes"},{"id":"D013256","term":"Steroids"},{"id":"D000072473","term":"Fused-Ring Compounds"},{"id":"D013259","term":"Steroids, Fluorinated"}]}},"hasResults":true}